Praziquantel pharmacokinetics and side effects in schistosoma japonicum-lnfected patients with liver disease

Journal of Infectious Diseases

Volumn 157, Issue 3, 1988, Pages 530-535

  Watt, George ^a,b,c,d   White, Nick J ^a,b,c   Padre, Laurena ^a,b,c   Ritter, Wolfgang ^a,b,c   Fernando, Marcelino T ^a,b,c   Ranoa, Catherine P ^a,b,c   Laughlin, Larry W ^a,b,c  

^a University of Oxford ^*  (Philippines)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c BAYER AG   (Germany)

^d WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARASITIC AGENT; PRAZIQUANTEL;

ABDOMINAL PAIN; BIOAVAILABILITY; CLINICAL ARTICLE; DIARRHEA; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG THERAPY; FEMALE; HUMAN; LIVER DISEASE; MALE; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; SCHISTOSOMA JAPONICUM; SIDE EFFECT; TREMATODE;

BIOLOGICAL AVAILABILITY; FEMALE; HUMAN; LIVER DISEASES, PARASITIC; MALE; PRAZIQUANTEL; SCHISTOSOMIASIS JAPONICA; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, NON-P.H.S.;

EID: 0023876504     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/157.3.530     Document Type: Article

References (21)

1. Davis A. Recent advances in schistosomiasis. Q J Med 1986;58:95-110.
2. Pearson RD, Guerrant RL. Praziquantel: A major advance in antihelminthic therapy. Ann Intern Med 1983;99:195-8.
3. Frohberg H. Results of toxicological studies on praziquantel. Arzeimittelforschung 1984;34:1137-44.
4. Santos AT, Bias BL, Portillo JS, Nosenas O, Papasin M. Phase III clinical trials with praziquantel in S. japonicum infections in the Philippines. Arzeimittelforschung 1984;34: 1221-3.
5. Fu F-Y, Zheng J-S, Chen W-Q, Qin K-S, Meiying J, Xian L, Qingliang W, Songci L. Further experience with praziquantel in Schistosoma japonicum infections. Report of 716 cases. Chin Med J [Engl] 1984;97:47-52.
6. Chen M-G, Hua X-J, Wan Z-R, Weng Y, Wang M-J, Zhu P-J, He B-Z, Xu M-Y. Praziquantel in 237 cases of clonor-chiasis sinensis. Chin Med J [Engl] 1983;96:935-40.
7. Yogore MG Jr, Lewert RM, Bias BL. Schistosomiasis japon-ica in Barrio San Antonio, Bassey, Samar in the Philippines. V. Enzyme-linked immunosorbent assay (ELISA) compared with quantitative stool examination and the cir-cumoval precipitin (COP) test. Am J Trop Med Hyg 1981;30:1252-62.
8. Yogore MG Jr, Lewert RM, Silan RB. The circumoval precipitin (COP) test in schistosomiasis japonica. Am J Trop Med Hyg 1968;17:65-71.
9. Xiao XS, Catto BA, Webster LT. Quantitative determination of praziquantel in serum by high-performance liquid chromatography. J Chromatogr 1983;275:127-32.
10. Wegner DHG. The profile of the trematodicidal compound praziquantel. Arzeimittelforschung 1984;34:1132-6.
11. Hackett LW. Spleen measurements in malaria. Journal of the National Malaria Society 1944;3:121-33.
12. Olveda RM, Tiu E, Fevidal P Jr, de Veyra F Jr, Icatlo FC Jr, Domingo EO. Relationship of prevalence and intensity of infection to morbidity in schistosomiasis japonica: A study of three communities in Leyte, Philippines. Am J TYop Med Hyg 1983;32:1312-21.
13. Polderman AM, Gryseels B, Gerold JL, Kayiteshonga M, Manshande JP. Side effects of praziquantel in the treatment of Schistosoma mansoni in Maniema, Zaire. Trans R Soc Th>p Med Hyg 1984;78:752-4.
14. Watt G, Baldovino PC, Castro JT, Fernando MT, Ranoa CP. Bloody diarrhea after praziquantel therapy. Trans R Soc Trop Med Hyg 1986;80:345-6.
15. Steiner K, Garbe A, Diekman HW, Nowak H. The fate of praziquantel in the organism. I. Pharmacokinetics in animals. Eur J Drug Metab Pharmacokinet 1976;1:85-95.
16. Patzschke KE, Putter J, Wegner LA, Horster FA, Diekmann HW. Serum concentrations and renal excretion in humans after oral administration of praziquantel —results of three determination methods. Eur J Drug Metab Pharmacokinet 1979;4:149-56.
17. Leopold G, Ungethum W, Groll E, Diekman HW, Nowak H, Wegner DHG. Clinical pharmacology in normal volunteers of praziquantel, a new drug against schistosomes and cestodes: An example of a complex study covering both tolerance and pharmacokinetics. Eur J Clin Pharmacol 1978;14:281-91.
18. Wei CC, Xiu P, Zhonglu R, Li Y, Minglian L. Study on the pharmacokinetics of pyquiton (praziquantel) in late and chronic schistosomiasis japonica cases. Shanghai Medical Journal 1983;6:215-9.
19. Nosenas JS, Santos AT Jr, Bias BL, Turmis LC, Portillo GP, Poliquit OS, Papasin MC, Flores GS. Experiences with praziquantel against Schistosoma japonicum infection in the Philippines. Southeast Asian J Trop Med Public Health 1984;15:489-97.
20. Bunnag D, Pungpark S, Harinasuta T, Viravan C, Vanijanonta S, Suntharasamai P, Migasena S, Charoenlarp P, Riganti M, Looareesuwan S. Opisthorchis viverrini: Clinical experience with praziquantel in hospital for tropical diseases. Arzeimittelforschung 1984;34:1173-4.
21. Diekmann HW, Buhring KU. The fate of praziquantel in the organism. III. Metabolism in rat, beagle dog, and rhesus monkey. Eur J Drug Metab Pharmacokinet 1976;1:107-12.